Does the media prefer DMAC or WVE?

In the previous week, WAVE Life Sciences had 2 more articles in the media than DiaMedica Therapeutics. MarketBeat recorded 3 mentions for WAVE Life Sciences and 1 mentions for DiaMedica Therapeutics. WAVE Life Sciences' average media sentiment score of 0.10 beat DiaMedica Therapeutics' score of 0.00 indicating that WAVE Life Sciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment DiaMedica Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral WAVE Life Sciences 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has higher earnings and valuation, MPLT or DMAC?

DiaMedica Therapeutics is trading at a lower price-to-earnings ratio than Maplight Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Maplight Therapeutics N/A N/A -$161.15M -$40.99 N/A DiaMedica Therapeutics N/A N/A -$32.77M -$0.71 N/A

Is MPLT or DMAC more profitable?

Maplight Therapeutics' return on equity of 0.00% beat DiaMedica Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Maplight Therapeutics N/A N/A N/A DiaMedica Therapeutics N/A -77.15% -69.23%

Does the media favor MPLT or DMAC?

In the previous week, Maplight Therapeutics and Maplight Therapeutics both had 1 articles in the media. Maplight Therapeutics' average media sentiment score of 0.03 beat DiaMedica Therapeutics' score of 0.00 indicating that Maplight Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Maplight Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral DiaMedica Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to DMAC or PAHC?

In the previous week, Phibro Animal Health had 3 more articles in the media than DiaMedica Therapeutics. MarketBeat recorded 4 mentions for Phibro Animal Health and 1 mentions for DiaMedica Therapeutics. Phibro Animal Health's average media sentiment score of 0.59 beat DiaMedica Therapeutics' score of 0.00 indicating that Phibro Animal Health is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment DiaMedica Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Phibro Animal Health 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer DMAC or MRVI?

In the previous week, Maravai LifeSciences had 1 more articles in the media than DiaMedica Therapeutics. MarketBeat recorded 2 mentions for Maravai LifeSciences and 1 mentions for DiaMedica Therapeutics. Maravai LifeSciences' average media sentiment score of 0.29 beat DiaMedica Therapeutics' score of 0.00 indicating that Maravai LifeSciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment DiaMedica Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Maravai LifeSciences 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has stronger earnings & valuation, AVLN or DMAC?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Avalyn Pharma N/A N/A N/A N/A N/A DiaMedica Therapeutics N/A N/A -$32.77M -$0.71 N/A

Is AVLN or DMAC more profitable?

Avalyn Pharma's return on equity of 0.00% beat DiaMedica Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Avalyn Pharma N/A N/A N/A DiaMedica Therapeutics N/A -77.15% -69.23%

Does the media refer more to AVLN or DMAC?

In the previous week, Avalyn Pharma had 4 more articles in the media than DiaMedica Therapeutics. MarketBeat recorded 5 mentions for Avalyn Pharma and 1 mentions for DiaMedica Therapeutics. DiaMedica Therapeutics' average media sentiment score of 0.00 beat Avalyn Pharma's score of -0.50 indicating that DiaMedica Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Avalyn Pharma 0 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Negative DiaMedica Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

DiaMedica Therapeutics (DMAC) Competitors

$5.64 -0.20 (-3.42%)

Closing price 06/5/2026 04:00 PM Eastern

Extended Trading

$5.64 0.00 (-0.09%)

As of 06/5/2026 04:15 PM Eastern

Compare

DMAC vs. WVE, MPLT, PAHC, MRVI, and AVLN

Should you buy DiaMedica Therapeutics stock or one of its competitors? MarketBeat compares DiaMedica Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with DiaMedica Therapeutics include WAVE Life Sciences (WVE), Maplight Therapeutics (MPLT), Phibro Animal Health (PAHC), Maravai LifeSciences (MRVI), and Avalyn Pharma (AVLN). These companies are all part of the "pharmaceutical products" industry.

How does DiaMedica Therapeutics compare to WAVE Life Sciences?

DiaMedica Therapeutics (NASDAQ:DMAC) and WAVE Life Sciences (NASDAQ:WVE) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, valuation, dividends, analyst recommendations, risk, profitability, institutional ownership and earnings.

DiaMedica Therapeutics has higher earnings, but lower revenue than WAVE Life Sciences. DiaMedica Therapeutics is trading at a lower price-to-earnings ratio than WAVE Life Sciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
DiaMedica Therapeutics	N/A	N/A	-$32.77M	-$0.71	N/A
WAVE Life Sciences	$42.73M	25.80	-$204.38M	-$1.06	N/A

In the previous week, WAVE Life Sciences had 2 more articles in the media than DiaMedica Therapeutics. MarketBeat recorded 3 mentions for WAVE Life Sciences and 1 mentions for DiaMedica Therapeutics. WAVE Life Sciences' average media sentiment score of 0.10 beat DiaMedica Therapeutics' score of 0.00 indicating that WAVE Life Sciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
DiaMedica Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
WAVE Life Sciences	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

10.1% of DiaMedica Therapeutics shares are owned by institutional investors. Comparatively, 89.7% of WAVE Life Sciences shares are owned by institutional investors. 5.0% of DiaMedica Therapeutics shares are owned by insiders. Comparatively, 24.3% of WAVE Life Sciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

DiaMedica Therapeutics has a beta of 0.97, indicating that its share price is 3% less volatile than the broader market. Comparatively, WAVE Life Sciences has a beta of -1.33, indicating that its share price is 233% less volatile than the broader market.

DiaMedica Therapeutics has a net margin of 0.00% compared to WAVE Life Sciences' net margin of -255.70%. WAVE Life Sciences' return on equity of -56.76% beat DiaMedica Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
DiaMedica Therapeutics	N/A	-77.15%	-69.23%
WAVE Life Sciences	-255.70%	-56.76%	-42.80%

DiaMedica Therapeutics presently has a consensus target price of $12.33, suggesting a potential upside of 118.68%. WAVE Life Sciences has a consensus target price of $27.25, suggesting a potential upside of 375.57%. Given WAVE Life Sciences' stronger consensus rating and higher possible upside, analysts clearly believe WAVE Life Sciences is more favorable than DiaMedica Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
DiaMedica Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67
WAVE Life Sciences	1 Sell rating(s)	0 Hold rating(s)	14 Buy rating(s)	0 Strong Buy rating(s)	2.87

Summary

WAVE Life Sciences beats DiaMedica Therapeutics on 11 of the 15 factors compared between the two stocks.

How does DiaMedica Therapeutics compare to Maplight Therapeutics?

Maplight Therapeutics (NASDAQ:MPLT) and DiaMedica Therapeutics (NASDAQ:DMAC) are both small-cap pharmaceutical products companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, media sentiment, dividends, earnings, profitability, risk and institutional ownership.

Maplight Therapeutics presently has a consensus price target of $37.78, suggesting a potential upside of 34.87%. DiaMedica Therapeutics has a consensus price target of $12.33, suggesting a potential upside of 118.68%. Given DiaMedica Therapeutics' higher probable upside, analysts clearly believe DiaMedica Therapeutics is more favorable than Maplight Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Maplight Therapeutics	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	3 Strong Buy rating(s)	3.00
DiaMedica Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67

In the previous week, Maplight Therapeutics and Maplight Therapeutics both had 1 articles in the media. Maplight Therapeutics' average media sentiment score of 0.03 beat DiaMedica Therapeutics' score of 0.00 indicating that Maplight Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Maplight Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
DiaMedica Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

10.1% of DiaMedica Therapeutics shares are held by institutional investors. 3.8% of Maplight Therapeutics shares are held by company insiders. Comparatively, 5.0% of DiaMedica Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Maplight Therapeutics' return on equity of 0.00% beat DiaMedica Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Maplight Therapeutics	N/A	N/A	N/A
DiaMedica Therapeutics	N/A	-77.15%	-69.23%

DiaMedica Therapeutics is trading at a lower price-to-earnings ratio than Maplight Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Maplight Therapeutics	N/A	N/A	-$161.15M	-$40.99	N/A
DiaMedica Therapeutics	N/A	N/A	-$32.77M	-$0.71	N/A

Summary

Maplight Therapeutics beats DiaMedica Therapeutics on 7 of the 12 factors compared between the two stocks.

How does DiaMedica Therapeutics compare to Phibro Animal Health?

DiaMedica Therapeutics (NASDAQ:DMAC) and Phibro Animal Health (NASDAQ:PAHC) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, earnings, media sentiment, profitability, dividends, risk and institutional ownership.

Phibro Animal Health has a net margin of 6.35% compared to DiaMedica Therapeutics' net margin of 0.00%. Phibro Animal Health's return on equity of 37.14% beat DiaMedica Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
DiaMedica Therapeutics	N/A	-77.15%	-69.23%
Phibro Animal Health	6.35%	37.14%	8.57%

10.1% of DiaMedica Therapeutics shares are held by institutional investors. Comparatively, 99.3% of Phibro Animal Health shares are held by institutional investors. 5.0% of DiaMedica Therapeutics shares are held by insiders. Comparatively, 50.1% of Phibro Animal Health shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

DiaMedica Therapeutics currently has a consensus target price of $12.33, suggesting a potential upside of 118.68%. Phibro Animal Health has a consensus target price of $38.80, suggesting a potential upside of 19.64%. Given DiaMedica Therapeutics' stronger consensus rating and higher probable upside, equities research analysts clearly believe DiaMedica Therapeutics is more favorable than Phibro Animal Health.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
DiaMedica Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67
Phibro Animal Health	1 Sell rating(s)	4 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.14

Phibro Animal Health has higher revenue and earnings than DiaMedica Therapeutics. DiaMedica Therapeutics is trading at a lower price-to-earnings ratio than Phibro Animal Health, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
DiaMedica Therapeutics	N/A	N/A	-$32.77M	-$0.71	N/A
Phibro Animal Health	$1.30B	1.01	$48.26M	$2.33	13.92

In the previous week, Phibro Animal Health had 3 more articles in the media than DiaMedica Therapeutics. MarketBeat recorded 4 mentions for Phibro Animal Health and 1 mentions for DiaMedica Therapeutics. Phibro Animal Health's average media sentiment score of 0.59 beat DiaMedica Therapeutics' score of 0.00 indicating that Phibro Animal Health is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
DiaMedica Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Phibro Animal Health	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

DiaMedica Therapeutics has a beta of 0.97, suggesting that its share price is 3% less volatile than the broader market. Comparatively, Phibro Animal Health has a beta of 0.46, suggesting that its share price is 54% less volatile than the broader market.

Summary

Phibro Animal Health beats DiaMedica Therapeutics on 11 of the 15 factors compared between the two stocks.

How does DiaMedica Therapeutics compare to Maravai LifeSciences?

DiaMedica Therapeutics (NASDAQ:DMAC) and Maravai LifeSciences (NASDAQ:MRVI) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their analyst recommendations, media sentiment, dividends, earnings, valuation, profitability, risk and institutional ownership.

DiaMedica Therapeutics has higher earnings, but lower revenue than Maravai LifeSciences. DiaMedica Therapeutics is trading at a lower price-to-earnings ratio than Maravai LifeSciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
DiaMedica Therapeutics	N/A	N/A	-$32.77M	-$0.71	N/A
Maravai LifeSciences	$185.74M	6.98	-$130.77M	-$0.71	N/A

In the previous week, Maravai LifeSciences had 1 more articles in the media than DiaMedica Therapeutics. MarketBeat recorded 2 mentions for Maravai LifeSciences and 1 mentions for DiaMedica Therapeutics. Maravai LifeSciences' average media sentiment score of 0.29 beat DiaMedica Therapeutics' score of 0.00 indicating that Maravai LifeSciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
DiaMedica Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Maravai LifeSciences	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

DiaMedica Therapeutics presently has a consensus price target of $12.33, suggesting a potential upside of 118.68%. Maravai LifeSciences has a consensus price target of $5.50, suggesting a potential upside of 9.56%. Given DiaMedica Therapeutics' stronger consensus rating and higher possible upside, research analysts plainly believe DiaMedica Therapeutics is more favorable than Maravai LifeSciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
DiaMedica Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67
Maravai LifeSciences	2 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.20

DiaMedica Therapeutics has a net margin of 0.00% compared to Maravai LifeSciences' net margin of -51.07%. Maravai LifeSciences' return on equity of -17.87% beat DiaMedica Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
DiaMedica Therapeutics	N/A	-77.15%	-69.23%
Maravai LifeSciences	-51.07%	-17.87%	-9.08%

DiaMedica Therapeutics has a beta of 0.97, suggesting that its stock price is 3% less volatile than the broader market. Comparatively, Maravai LifeSciences has a beta of 0.72, suggesting that its stock price is 28% less volatile than the broader market.

10.1% of DiaMedica Therapeutics shares are owned by institutional investors. Comparatively, 50.3% of Maravai LifeSciences shares are owned by institutional investors. 5.0% of DiaMedica Therapeutics shares are owned by company insiders. Comparatively, 2.5% of Maravai LifeSciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

DiaMedica Therapeutics and Maravai LifeSciences tied by winning 7 of the 14 factors compared between the two stocks.

How does DiaMedica Therapeutics compare to Avalyn Pharma?

Avalyn Pharma (NASDAQ:AVLN) and DiaMedica Therapeutics (NASDAQ:DMAC) are both small-cap pharmaceutical products companies, but which is the superior business? We will contrast the two businesses based on the strength of their media sentiment, risk, institutional ownership, valuation, profitability, earnings, analyst recommendations and dividends.

In the previous week, Avalyn Pharma had 4 more articles in the media than DiaMedica Therapeutics. MarketBeat recorded 5 mentions for Avalyn Pharma and 1 mentions for DiaMedica Therapeutics. DiaMedica Therapeutics' average media sentiment score of 0.00 beat Avalyn Pharma's score of -0.50 indicating that DiaMedica Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Avalyn Pharma	0 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Negative
DiaMedica Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Avalyn Pharma presently has a consensus target price of $59.00, suggesting a potential upside of 118.03%. DiaMedica Therapeutics has a consensus target price of $12.33, suggesting a potential upside of 118.68%. Given DiaMedica Therapeutics' higher possible upside, analysts plainly believe DiaMedica Therapeutics is more favorable than Avalyn Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Avalyn Pharma	0 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	2 Strong Buy rating(s)	3.20
DiaMedica Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Avalyn Pharma	N/A	N/A	N/A	N/A	N/A
DiaMedica Therapeutics	N/A	N/A	-$32.77M	-$0.71	N/A

Avalyn Pharma's return on equity of 0.00% beat DiaMedica Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Avalyn Pharma	N/A	N/A	N/A
DiaMedica Therapeutics	N/A	-77.15%	-69.23%

10.1% of DiaMedica Therapeutics shares are owned by institutional investors. 5.0% of DiaMedica Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Summary

Avalyn Pharma and DiaMedica Therapeutics tied by winning 5 of the 10 factors compared between the two stocks.

Get DiaMedica Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding DMAC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

DMAC vs. The Competition

Export

Metric	DiaMedica Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$314.68M	$3.35B	$6.46B	$12.43B
Dividend Yield	N/A	2.33%	2.68%	5.33%
P/E Ratio	-7.94	18.85	23.79	23.63
Price / Sales	N/A	308.39	543.57	124.89
Price / Cash	N/A	114.83	42.35	57.17
Price / Book	5.22	6.51	9.73	6.35
Net Income	-$32.77M	$24.15M	$3.57B	$337.59M
7 Day Performance	-5.84%	-6.96%	-1.25%	-2.51%
1 Month Performance	-13.50%	-4.27%	0.83%	-0.68%
1 Year Performance	36.23%	36.81%	24.11%	25.38%

DiaMedica Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
DMAC DiaMedica Therapeutics	1.3288 of 5 stars	$5.64 -3.4%	$12.33 +118.7%	+37.9%	$314.68M	N/A	N/A	20	Analyst Upgrade Gap Down
WVE WAVE Life Sciences	2.7441 of 5 stars	$6.58 +1.7%	$27.25 +314.1%	-15.1%	$1.27B	$42.73M	N/A	240
MPLT Maplight Therapeutics	3.6667 of 5 stars	$29.31 -1.6%	$36.89 +25.9%	N/A	$1.25B	N/A	N/A	109
PAHC Phibro Animal Health	4.785 of 5 stars	$30.79 -3.3%	$38.80 +26.0%	+35.7%	$1.25B	$1.30B	13.21	2,475
MRVI Maravai LifeSciences	2.0591 of 5 stars	$4.80 +3.4%	$5.50 +14.6%	+131.3%	$1.24B	$185.74M	N/A	610	Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:DMAC) was last updated on 6/6/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

DiaMedica Therapeutics (DMAC) Competitors

DMAC vs. WVE, MPLT, PAHC, MRVI, and AVLN

How does DiaMedica Therapeutics compare to WAVE Life Sciences?

Summary

How does DiaMedica Therapeutics compare to Maplight Therapeutics?

Summary

How does DiaMedica Therapeutics compare to Phibro Animal Health?

Summary

How does DiaMedica Therapeutics compare to Maravai LifeSciences?

Summary

How does DiaMedica Therapeutics compare to Avalyn Pharma?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

DMAC vs. The Competition

DiaMedica Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

DiaMedica Therapeutics (DMAC) Competitors

DMAC vs. WVE, MPLT, PAHC, MRVI, and AVLN

How does DiaMedica Therapeutics compare to WAVE Life Sciences?

Which has higher valuation and earnings, DMAC or WVE?

Does the media prefer DMAC or WVE?

Do institutionals and insiders hold more shares of DMAC or WVE?

Which has more volatility and risk, DMAC or WVE?

Is DMAC or WVE more profitable?

Do analysts recommend DMAC or WVE?

Summary

How does DiaMedica Therapeutics compare to Maplight Therapeutics?

Do analysts rate MPLT or DMAC?

Does the media favor MPLT or DMAC?

Do insiders and institutionals have more ownership in MPLT or DMAC?

Is MPLT or DMAC more profitable?

Which has higher earnings and valuation, MPLT or DMAC?

Summary

How does DiaMedica Therapeutics compare to Phibro Animal Health?

Is DMAC or PAHC more profitable?

Do insiders & institutionals hold more shares of DMAC or PAHC?

Do analysts rate DMAC or PAHC?

Which has preferable valuation and earnings, DMAC or PAHC?

Does the media refer more to DMAC or PAHC?

Which has more risk & volatility, DMAC or PAHC?

Summary

How does DiaMedica Therapeutics compare to Maravai LifeSciences?

Which has better earnings & valuation, DMAC or MRVI?

Does the media prefer DMAC or MRVI?

Do analysts rate DMAC or MRVI?

Is DMAC or MRVI more profitable?

Which has more risk and volatility, DMAC or MRVI?

Do institutionals and insiders hold more shares of DMAC or MRVI?

Summary

How does DiaMedica Therapeutics compare to Avalyn Pharma?

Does the media refer more to AVLN or DMAC?

Do analysts rate AVLN or DMAC?

Which has stronger earnings & valuation, AVLN or DMAC?

Is AVLN or DMAC more profitable?

Do institutionals & insiders have more ownership in AVLN or DMAC?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

DMAC vs. The Competition

DiaMedica Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools